文献速递白血病造血干细胞移植与细胞治疗

CD3阴性单核细胞定量嵌合率预测急性髓系白血病移植后预后

Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.
PubMed 文献 · Leukemia · 2019-11-25

该单中心回顾性研究纳入100例接受异基因造血干细胞移植的急性髓系白血病(AML)患者,评估CD3阴性单核细胞定量嵌合率(RQ-PCR法)对复发预测的价值并与WT1定量比较。结果显示未达完全嵌合(受者DNA≥0.01%)者复发风险显著增高、总生存更低,CD3阴性细胞嵌合率与WT1预测复发性能相当。

要点

  • CD3阴性细胞受者DNA≥0.01%者复发风险显著增高且总生存更低。
  • CD3阴性细胞受者DNA比例升高与复发风险增加相关,但与总生存无关。
  • CD3阴性细胞嵌合率与WT1预测复发性能相当,敏感度82%对78%,特异度均100%。

核心结论

  • CD3阴性单核细胞定量特异性嵌合率是监测可测量残留病的有力新工具,可用于无可用分子标志物的AML患者。

研究设计与样本

  • 单中心回顾性分析100例因AML接受异基因造血干细胞移植的患者,采用RQ-PCR监测CD3阴性单核细胞嵌合率并与WT1定量比较。

主要发现

  • 未达完全嵌合(CD3阴性细胞中受者DNA≥0.01%)者复发风险显著更高且总生存更低(p<0.001)。
  • CD3阴性细胞中受者DNA比例升高与复发风险增加相关(p<0.001),但与总生存无关。
  • CD3阴性细胞嵌合率与WT1表达预测复发性能相当,可早于血液学复发90天以上,敏感度分别为82%和78%,特异度均100%。

关键数值与推荐

  • 完全嵌合定义为CD3阴性细胞中受者DNA<0.01%。
  • CD3阴性细胞嵌合率预测复发敏感度82%、特异度100%;WT1敏感度78%、特异度100%。

临床怎么用

  • 对移植后AML患者可监测CD3阴性单核细胞定量嵌合率以预警复发,尤其适用于缺乏分子标志物者。

局限性

  • 单中心回顾性研究,样本量100例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is a major complication of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate chimerism monitoring on the CD3-negative mononuclear cells by RQ-PCR to predict relapse of patients allografted for AML and to compare its performance with WT1 quantification. A cohort of 100 patients undergoing allogenic SCT for AML was retrospectively analyzed in a single institution. Patients without complete chimerism, defined as less than 0.01% of recipient's DNA in CD3-negative cells, had a significantly higher risk of relapse and a lower overall survival (p < 0.001). An increase in the percentage of recipient DNA in CD3-negative cells was associated with an increased risk of relapse (p < 0.001) but not with overall survival. Comparable performances between monitoring of CD3-negative cell chimerism and WT1 expression to predict relapse was observed up to more than 90 days before hematological relapse, with sensitivity of 82% and 78%, respectively, and specificity of 100% for both approaches. Quantitative specific chimerism of the CD3-negative mononuclear fraction, enriched in blastic cells, is a new and powerful tool for monitoring measurable residual disease and could be used for AML patients without available molecular markers.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bouvier A, Riou J, Thépot S, et al. Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation. Leukemia. 2019. PMID: 31768015. doi:10.1038/s41375-019-0624-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。